AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

We recently published a list of 10 Best Foreign Stocks To Buy Now. In this article, we are going to take a look at where ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

AstraZeneca and Daiichi’s ADC datopotamab deruxtecan (Dato-DXd) has the same mechanism as Trodelvy. But improvements in progression-free survival (PFS) and response rates, endpoints that Gilead ...